Global Gene Editing Market 2025-2035

Description

List of Tables

Gene Editing Market Size, Share & Trends Analysis Report by Type (Reagents & Consumables, and Software & Systems), by Technology (CRISPR, TALENS, ZFN, Base Editing, Antisense, RNAI, Other Technologies), by Application (Cell Line Engineering, Genome Editing, Drug Discovery & Development, Other Applications), by End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, CROS & CDMOS, Other End Users) Forecast Period (2025-2035)

Industry Overview

Gene editing market, valued at $4,852 million in 2024, grew to $5,245 million in 2025 and is projected to expand at a robust CAGR of 8.5% between 2025 and 2035, reaching an estimated value of $11,870 million by the end of the forecast period. The increasing digitalization of healthcare infrastructure has been contributing to the global market growth of gene editing. Gene editing is a revolutionary biotechnology that enables precise modifications to DNA, offering transformative potential across healthcare, agriculture, and research. Researchers are looking into using gene-editing as a treatment for a variety of diseases, such as cancer, heart disease, diabetes, AIDS, and Alzheimer's, to rare genetic disorders such as muscular dystrophy. This technique makes it easier for scientists to alter the fundamental components of life. The industry's momentum is further fueled by growing private investment and government support, especially in the U.S. and Asia-Pacific. For instance, in December 2023, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of Sickle Cell Disease (SCD) in patients 12 years and older. Casgevy is the first FDA-approved treatment to utilize a type of novel genome editing technology, making an innovative advancement in the field of gene therapy.

Market Dynamics

Impact of Trade Tensions on the Gene Editing Market

Ongoing trade tensions between major global powers such as the United States, China, and the European Union are increasingly affecting the gene editing market. For instance, U.S. tariffs on biotechnology tools and genetic sequencing equipment, many of which are imported from China, have increased the cost of lab technologies used in gene editing research and development. Similarly, retaliatory trade policies and regulatory hurdles imposed by the EU and China have disrupted cross-border collaborations and slowed the global movement of gene-editing materials and expertise.

In regions such as Asia-Pacific, where gene editing is increasingly expanding in agriculture and healthcare, reliance on imported genomic tools and CRISPR-related technologies makes them vulnerable to price increases and supply chain delays. Trade barriers can hinder research progress and limit access to cutting-edge technologies, particularly in emerging markets where local production capacity is still under development.

Overall, these geopolitical challenges are prompting biotech companies and research institutions to diversify their supply chains, localize production, and forge new international partnerships. Continued support from national governments, such as India's genome editing guidelines and public funding initiatives, or the U.S. government's investment in the Safe Genes program, is important for sustaining innovation and ensuring that gene editing technologies remain accessible and affordable across borders.

CRISPR Technology to Hold a Significant Share in the Market

Based on technology, CRISPR holds a significant share, attributed to the major advantages over its alternatives, such as TALENs and ZFN. CRISPR has become a powerful tool in genetic engineering that helps researchers to modify genes with better precision and efficiency. The discovery of CRISPR has had a profound impact on various scientific fields, from medicine and agriculture to basic research and biotechnology. CRISPR gene editing technology has led to various significant advancements across various fields. For instance, in May 2025, a child diagnosed with a rare genetic disorder was successfully treated with a customized CRISPR gene editing therapy by a team at Children's Hospital of Philadelphia (CHOP) and Penn Medicine. Another notable achievement includes Precision gene editing, treatment of genetic diseases, cancer therapies, functional genomics, and agricultural advancements, among others.

Market Segmentation

Based on the type, the market is segmented into reagents & consumables and software & systems.
Based on technology, the market is segmented into CRISPR, TALENS, ZFN, base editing, antisense, RNAI, and other technologies.
Based on the application, the market is segmented into cell line engineering, genome editing, drug discovery & development, and other applications.
Based on the end-user, the market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, CROS & CDMOS, and other end-users.

Drug Discovery and Development Segment Holds the Prominent Share of the Global Gene Editing Market

The global gene editing market is segmented into drug discovery and development and diagnostics. The drug discovery and development segment occupies the largest market share. This can be attributed to the fact that gene editing technologies, especially CRISPR, are being widely used for the identification of novel drug targets and understanding the genetic basis of a patient's disease. The utilization of genome editing technologies for diagnostics is expected to increase over the years, owing to the potential of these technologies in the early screening/diagnosis of genetic and chronic diseases.

Regional Outlook

The global gene editing market is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

North America holds the Largest Share in the Global Gene Editing Market

The North American gene editing market holds the largest share of the market. This is due to the increase in the prevalence of chronic disease, a growing preference for gene therapies, and an increase in private and public sector funding. The U.S., in particular, leads in clinical trials, biotech innovation, and government-backed initiatives such as the NIH's Somatic Cell Genome Editing (SCGE) program. For instance, in June 2025, Lilly acquired Verve Therapeutics in a $1.3 billion deal targeting one-time gene-editing treatments for cardiovascular disease. The acquisition highlights growing industry momentum toward single-course genetic medicines that aim to address the root causes of disease with durable, potentially lifelong effects.

Asia Pacific is Expected to be the Fastest-Growing Region

The Asia Pacific region is the fastest-growing market for gene editing technologies, driven by substantial investments in research and development, particularly in countries like China, Japan, and South Korea. These nations are prioritizing personalized and precision medicine, supported by advancements in gene editing tools and strong government backing. The region's large population and high rate of genetic disorders such as thalassemia, sickle cell anemia, and various cancers are creating a significant demand for innovative treatments. Additionally, the thriving biotechnology and pharmaceutical sectors in countries such as China and India are further propelling market growth.

Market Players Outlook

The major companies operating in the global gene editing market include Agilent Technologies, Inc., GenScript Biotech Corp., Merck KGaA, Precision BioSciences, Inc., and Thermo Fisher Scientific Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

In May 2025, NKure Therapeutics, along with CRISPR Therapeutics, worked to jointly develop an off-the-shelf CAR-T cell therapy for treating cancer. The partnership aimed to leverage CRISPR's advanced gene editing technology and NKure's expertise in cell therapy to create an accessible CAR-T therapy, making cancer immunotherapy available to patients.
In April 2024, Regeneron and Mammoth Biosciences collaborated to develop next-generation in vivo gene editing therapies. They did develop therapies in conjunction with in vivo next-generation gene editing. The partnership has combined Regeneron's genetic medicine expertise with Mammoth's novel CRISPR-based gene editing technology, so it sought out chances for treating many serious diseases while broadening precise and effective genetic medicines.
In September 2024, Corteva partnered with Pairwise for a five-year joint venture to accelerate the development and delivery of advanced gene editing solutions aimed at improving climate resilience in agriculture. Corteva invested close to $25 million in Pairwise to assist with expanding gene editing in several specialty and staple crops. In order to engineer some crops that can be more resilient with regard to climate change and harsh weather, the companies' combined all of the expertise that was available.

The Report Covers:

Market value data analysis of 2024 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global gene editing market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2028898

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Gene Editing Market Sales Analysis - Type | Technology | Application | End-User ($ Million)
Gene Editing Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Gene Editing Trends
- 2.2.2. Market Recommendations

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For the Global Gene Editing Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For the Global Gene Editing Market: Impact Analysis
3.3. Market Opportunities

4. Competitive Landscape

4.1. Competitive Dashboard - Gene Editing Market Revenue and Share by Manufacturers
Gene Editing Product Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. Agilent Technologies, Inc.
  - 4.2.1.1. Overview
  - 4.2.1.2. Product Portfolio
  - 4.2.1.3. Financial Analysis (Subject to Data Availability)
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. GenScript Biotech Corp.
  - 4.2.2.1. Overview
  - 4.2.2.2. Product Portfolio
  - 4.2.2.3. Financial Analysis (Subject to Data Availability)
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. Merck KGaA
  - 4.2.3.1. Overview
  - 4.2.3.2. Product Portfolio
  - 4.2.3.3. Financial Analysis (Subject to Data Availability)
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. Precision BioSciences, Inc.
  - 4.2.4.1. Overview
  - 4.2.4.2. Product Portfolio
  - 4.2.4.3. Financial Analysis (Subject to Data Availability)
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. Thermo Fisher Scientific Inc.
  - 4.2.5.1. Overview
  - 4.2.5.2. Product Portfolio
  - 4.2.5.3. Financial Analysis (Subject to Data Availability)
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. Global Gene Editing Market Sales Analysis By Type ($ Million)

5.1. Reagents & Consumables
5.2. Software & Systems

6. Global Gene Editing Market Sales Analysis By Technology ($ Million)

6.1. CRISPR
6.2. TALENS
6.3. ZFN
6.4. Base Editing
6.5. Antisense
6.6. RNAI
6.7. Other Technologies

7. Global Gene Editing Market Sales Analysis By Application ($ Million)

7.1. Cell Line Engineering
7.2. Genome Editing
7.3. Drug Discovery & Development
7.4. Other Applications

8. Global Gene Editing Market Sales Analysis By End-User ($ Million)

8.1. Pharmaceutical & Biotechnology Companies
8.2. Academic & Research Institutes
8.3. CROS & CDMOS
8.4. Other End Users

9. Regional Analysis

9.1. North American Gene Editing Market Sales Analysis - Type | Technology | Application | End-User ($ Million)
Macroeconomic Factors for North America
- 9.1.1. United States
- 9.1.2. Canada
9.2. European Gene Editing Market Sales Analysis - Type | Technology | Application | End-User ($ Million)
Macroeconomic Factors for Europe
- 9.2.1. UK
- 9.2.2. Germany
- 9.2.3. Italy
- 9.2.4. Spain
- 9.2.5. France
- 9.2.6. Russia
- 9.2.7. Rest of Europe
9.3. Asia-Pacific Gene Editing Market Sales Analysis - Type | Technology | Application | End-User ($ Million)
Macroeconomic Factors for Asia-Pacific
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. South Korea
- 9.3.4. India
- 9.3.5. Australia & New Zealand
- 9.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And others)
- 9.3.7. Rest of Asia-Pacific
9.4. Rest of the World Gene Editing Market Sales Analysis - Type | Technology | Application | End-User ($ Million)
Macroeconomic Factors for the Rest of the World
- 9.4.1. Latin America
- 9.4.2. Middle East and Africa

10. Company Profiles

10.1. Agilent Technologies, Inc.
- 10.1.1. Quick Facts
- 10.1.2. Company Overview
- 10.1.3. Product Portfolio
- 10.1.4. Business Strategies
10.2. Allele Biotechnology and Pharmaceuticals Inc.
- 10.2.1. Quick Facts
- 10.2.2. Company Overview
- 10.2.3. Product Portfolio
- 10.2.4. Business Strategies
10.3. AMS Biotechnology (Europe) Ltd.
- 10.3.1. Quick Facts
- 10.3.2. Company Overview
- 10.3.3. Product Portfolio
- 10.3.4. Business Strategies
10.4. Axol Bioscience Ltd.
- 10.4.1. Quick Facts
- 10.4.2. Company Overview
- 10.4.3. Product Portfolio
- 10.4.4. Business Strategies
10.5. Beam Therapeutics
- 10.5.1. Quick Facts
- 10.5.2. Company Overview
- 10.5.3. Product Portfolio
- 10.5.4. Business Strategies
10.6. BioCat GmbH
- 10.6.1. Quick Facts
- 10.6.2. Company Overview
- 10.6.3. Product Portfolio
- 10.6.4. Business Strategies
10.7. Bioneer A/S
- 10.7.1. Quick Facts
- 10.7.2. Company Overview
- 10.7.3. Product Portfolio
- 10.7.4. Business Strategies
10.8. Caribou Biosciences, Inc.
- 10.8.1. Quick Facts
- 10.8.2. Company Overview
- 10.8.3. Product Portfolio
- 10.8.4. Business Strategies
10.9. Cellecta, Inc.
- 10.9.1. Quick Facts
- 10.9.2. Company Overview
- 10.9.3. Product Portfolio
- 10.9.4. Business Strategies
10.10. COBO Technologies Aps
- 10.10.1. Quick Facts
- 10.10.2. Company Overview
- 10.10.3. Product Portfolio
- 10.10.4. Business Strategies
10.11. Editas Medicine, Inc.
- 10.11.1. Quick Facts
- 10.11.2. Company Overview
- 10.11.3. Product Portfolio
- 10.11.4. Business Strategies
10.12. GeneCopoeia, Inc.
- 10.12.1. Quick Facts
- 10.12.2. Company Overview
- 10.12.3. Product Portfolio
- 10.12.4. Business Strategies
10.13. GenScript Biotech Corp.
- 10.13.1. Quick Facts
- 10.13.2. Company Overview
- 10.13.3. Product Portfolio
- 10.13.4. Business Strategies
10.14. Hera Biolabs.
- 10.14.1. Quick Facts
- 10.14.2. Company Overview
- 10.14.3. Product Portfolio
- 10.14.4. Business Strategies
10.15. Integrated DNA Technologies, Inc.
- 10.15.1. Quick Facts
- 10.15.2. Company Overview
- 10.15.3. Product Portfolio
- 10.15.4. Business Strategies
10.16. Merck KGaA
- 10.16.1. Quick Facts
- 10.16.2. Company Overview
- 10.16.3. Product Portfolio
- 10.16.4. Business Strategies
10.17. New England Biolabs, Inc.
- 10.17.1. Quick Facts
- 10.17.2. Company Overview
- 10.17.3. Product Portfolio
- 10.17.4. Business Strategies
10.18. OriGene Technologies, Inc.
- 10.18.1. Quick Facts
- 10.18.2. Company Overview
- 10.18.3. Product Portfolio
- 10.18.4. Business Strategies
10.19. Precision BioSciences, Inc.
- 10.19.1. Quick Facts
- 10.19.2. Company Overview
- 10.19.3. Product Portfolio
- 10.19.4. Business Strategies
10.20. RECOMBINETICS
- 10.20.1. Quick Facts
- 10.20.2. Company Overview
- 10.20.3. Product Portfolio
- 10.20.4. Business Strategies
10.21. REPROCELL Inc.
- 10.21.1. Quick Facts
- 10.21.2. Company Overview
- 10.21.3. Product Portfolio
- 10.21.4. Business Strategies
10.22. Revvity Discovery Ltd.
- 10.22.1. Quick Facts
- 10.22.2. Company Overview
- 10.22.3. Product Portfolio
- 10.22.4. Business Strategies
10.23. Takara Bio Inc.
- 10.23.1. Quick Facts
- 10.23.2. Company Overview
- 10.23.3. Product Portfolio
- 10.23.4. Business Strategies
10.24. Thermo Fisher Scientific Inc.
- 10.24.1. Quick Facts
- 10.24.2. Company Overview
- 10.24.3. Product Portfolio
- 10.24.4. Business Strategies
10.25. TimeDoc, Inc.
- 10.25.1. Quick Facts
- 10.25.2. Company Overview
- 10.25.3. Product Portfolio
- 10.25.4. Business Strategies
10.26. Tropic Biosciences UK Ltd
- 10.26.1. Quick Facts
- 10.26.2. Company Overview
- 10.26.3. Product Portfolio
- 10.26.4. Business Strategies
10.27. VitalTech
- 10.27.1. Quick Facts
- 10.27.2. Company Overview
- 10.27.3. Product Portfolio
- 10.27.4. Business Strategies
10.28. WellSky Corp.
- 10.28.1. Quick Facts
- 10.28.2. Company Overview
- 10.28.3. Product Portfolio
- 10.28.4. Business Strategies
10.29. ZeOmega, Inc.
- 10.29.1. Quick Facts
- 10.29.2. Company Overview
- 10.29.3. Product Portfolio
- 10.29.4. Business Strategies